Physician profile
Mark Brus
NPI 1922097948
$13,167.78
in general payments reported to CMS, 2019-2025
63 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $1,073 · 2021: $1,156 · 2022: $2,115 · 2023: $2,593 · 2024: $2,401 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,077 · Entertainment: $13.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,077.24 |
| Entertainment | $13.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.25 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Pfizer INC. | $1,325.74 | 2019-2025 | |
| Lilly USA, LLC | $1,200.11 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $901.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $860.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $775.13 | 2021-2025 | |
| Amgen INC. | $758.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $678.27 | 2019-2023 | Verquvo, Belsomra, Januvia |
| Sumitomo Pharma America, INC. | $612.25 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $583.47 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.21 | 2019-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $346.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $204.80 | 2019-2025 | |
| Ibsa Pharma INC. | $202.30 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $196.67 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.